A new study evaluates associations between nearly 200 environmental exposures and Alzheimer's disease and other dementias.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On ...

Learn more Xenon Pharmaceuticals (XENE) provided investors with two very different updates on the same drug, and Wall Street paid attention to the troubling one. Shares of the Vancouver-based biotech ...

The aliens were next door, and somebody killed them. That’s the story plasma physicist John Brandenburg, PhD, tells about ...

Sept 17 (Reuters) - Xenon Pharmaceuticals (XENE.O), opens new tab on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for ‌major and ...

Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a 10-month low. The drug at the center of ...

Destructive immune cells tied to Alzheimer’s disease may get their marching orders from cells outside the brain rather than within it. In mice, suppressing a small population of immune cells located ...

The action comes one week after Biohaven paused trials of a rival drug candidate. (cagkansayin/ iStock/Getty Images Plus) Xenon Pharmaceuticals has paused enrollment in phase 3 depression trials after ...

Xenon's Azetukalner cut monthly focal seizures by 53.2% at the Phase 3 high dose, compared with 10.4% for placebo, in patients who had already tried a median of five seizure medicines. Xenon plans to ...

Xenon Pharmaceuticals Inc. XENE-Q stock sold off sharply Friday after the B.C. drug developer said it was temporarily halting enrolment in a late-stage human trial to see if its lead drug candidate, ...

Xenon Pharmaceuticals said it was voluntarily pausing enrollment for trials of azetukalner to treat depression and bipolar treatments, after adverse events occurred in the studies. The ...

Participants in Pittsburgh may never learn the results of their cognitive tests – and funding cuts that target ‘DEI’ have the potential to delay vital diagnoses Roderick Blair was surprised when ...